We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of Julyl 2022

Pipeline Chart

3 ADCs

  • Trastuzumab deruxtecan (T-DXd, DS-8201)
  • Patritumab deruxtecan (HER3-DXd, U3-1402)
  • Datopotamab deruxtecan (Dato-DXd, DS-1062)

BC: breast cancer, CRC: colorectal cancer,GC: gastric cancer, NSCLC: non-small celllung cancer, SCLC: small cell lung cancer, TNBC: triple negative breast cancer

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : Breakthrough designation (US)

Phase 1

  • (US/EU/Asia) HER2+ BC 2L~/ 1L
    DESTINY-Breast07
  • (US/EU/Asia) HER2 low BC
    Chemo naive/post chemo
    DESTINY-Breast08
  • (JP/US/EU/Asia) HER2+ GC combo, 2L~/1L
    DESTINY-Gastric03
  • (EU/Asia) HER2+ NSCLC
    (durvalumab combo) 1L
    DESTINY-Lung03
  • (US/EU) BC, bladder (nivolumab combo)
  • (US/EU) BC, NSCLC
    (pembrolizumab combo)
  • (US/EU/Asia) Solid tumors
    (AZD5305 combo)
    PETRA
  • (JP/US) NSCLC, TNBC, HR+ BC, SCLC,
    urothelial, GC, esophageal
    TROPION-PanTumor01
  • (CN) NSCLC, TNBC
    TROPION-PanTumor02
  • (JP/US/EU/Asia) NSCLC
    (w/o actionable mutation, pembrolizumab combo)
    TROPION-Lung02
  • (JP/US/EU) NSCLC
    (w/o actionable mutation, durvalumab combo)
    TROPION-Lung04
  • (US/EU/Asia) TNBC
    (durvalumab combo)
    BEGONIA
  • (JP/US/EU/Asia) Solid tumors
    (AZD5305 combo)
    PETRA
  • (JP/US/EU/Asia) NSCLC
  • (JP/US) EGFR mutated NSCLC
    (osimertinib combo)
  • (JP/US) HER3+ BC

Phase 2

  • (US/EU/Asia) TNBC
    (durvalumab combo)
    BEGONIA
  • (CN) HER2+ GC 3L
    DESTINY-Gastric06
  • (JP/US/EU) HER2+ NSCLC 2L∼
    DESTINY-Lung01
  • (JP/US/EU/Asia) HER2 mutated NSCLC 2L∼
    DESTINY-Lung02
  • (CN) HER2 mutated NSCLC 2L∼
    DESTINY-Lung05
  • (US/EU/Asia) NSCLC
    (durvalumab combo) 2L∼
    HUDSON
  • (JP/US/EU) HER2+ CRC 3L
    DESTINY-CRC01
  • (JP/US/EU/Asia) HER2+ CRC 3L
    DESTINY-CRC02
  • (JP/US/EU/Asia)
    HER2 mutated tumor
    DESTINY-PanTumor01
  • (US/EU/Asia)
    HER2 expressing tumor
    DESTINY-PanTumor02
  • (JP/US/EU/Asia) NSCLC
    (w/ actionable mutation)
    TROPION-Lung05
  • (JP/US/EU/Asia) EGFR mutated NSCLC 2L
    ORCHARD
  • (JP/US/EU/Asia)
    EGFR mutated NSCLC
    HERTHENA-Lung01

Phase 3

  • (JP/US/EU/Asia) HER2+ BC 3L
    DESTINY-Breast02
  • (JP/US/EU/Asia) HER2+ BC
    post neoadjuvant
    DESTINY-Breast05
  • (JP/US/EU/Asia) HER2 low BC
    chemo naive
    DESTINY-Breast06
  • (JP/US/EU/Asia) HER2+ BC 1L
    DESTINY-Breast09
  • (JP/US/EU/Asia) HER2+ BC
    neoadjuvant
    DESTINY-Breast11
  • (JP/EU/Asia) HER2+ GC 2L
    DESTINY-Gastric04
  • (JP/US/EU/Asia) NSCLC 1L
    (w/ exon 19 or exon 20 mutation)
    DESTINY-Lung04
  • (JP/US/EU/Asia) NSCLC 2/3L
    TROPION-Lung01
  • (JP/US/EU/Asia) NSCLC
    (w/o actionable mutation, pembro combo) 1L
    TROPION-Lung08
  • (JP/US/EU/Asia) HR+ BC 2/3L
    TROPION-Breast01
  • (JP/US/EU/Asia) TNBC 1L
    TROPION-Breast02
  • (JP/US/EU/Asia) EGFR mutated
    NSCLC 2L
    HERTHENA-Lung02

Submitted

  • (JP/US/EU/Asia) HER2+ BC 2L
    DESTINY-Breast03
  • (EU) HER2+ GC 2L
    DESTINY-Gastric02
  • (US) HER2 mutated NSCLC 2L∼
    DESTINY-Lung01
  • (JP/US/EU/Asia) HER2 low BC
    post chemo
    DESTINY-Lung01

Alpha

  • Oncology
  • Specialty Medicines
  • Vaccine

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma, FOP: Fibrodysplasia ossificans progressive, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, SCLC: small cell lung cancer, PTCL: peripheral T-cell lymphoma

  • : Project in oncology that is planned to be submitted for approval based on the results of phase 2 trials
  • : SAKIGAKE Designation (JP)
  • : Orphan drug designation (JP/US/EU)

Phase 1

  • DS-7300 (JP/US)
    B7-H3-directed ADC
    ESCC, CRPC, squamous NSCLC, etc.
  • DS-6000 (US)
    CDH6-directed ADC
    Renal cell carcinoma, ovarian cancer
  • DS-1055 (JP/US)
    Anti-GARP antibody
    Solid tumors
  • DS-1211 (US)
    TNAP inhibitor
    Pseudoxanthoma elasticum
  • DS-6016 (JP)
    Anti-ALK2 antibody
    Fibrodysplasia ossificans progressiva
  • DS-7011 (JP)
    Anti-TLR7 antibody
    Systemic lupus erythematosus
  • PLX2853 (US)
    BET inhibitor
    AML
  • PLX2853 (US)
    BET inhibitor
    Solid tumor
  • PLX2853 (US)
    BET inhibitor
    Gynecologic neoplasms, ovarian cancer
  • PLX2853 (US)
    BET inhibitor
    Prostate cancer
  • DS-1594 (US)
    Menin-MLL binding inhibitor
    AML, ALL
  • VN-0200 (JP)
    RS virus vaccine
    RS virus infection

Phase 2

  • Valemetostat (DS-3201) (JP/US/EU/Asia)
    EZH1/2 inhibitor
    PTCL
  • Valemetostat (DS-3201) (EU)
    EZH1/2 inhibitor
    BCL
  • DS-1001 (JP)
    Mutant IDH1 inhibitor
    Glioma
  • DS-7300 (JP/US/EU/Asia)
    B7-H3-directed ADC
    SCLC
  • DS-5141 (JP)
    ENA oligonucleotide DMD
  • DS-5670 (JP)
    SARS-CoV-2 mRNA vaccine
    COVID-19 (initial vaccination)

Phase 3

  • Quizartinib (JP/US/EU/Asia)
    FLT3 inhibitor
    1L AML
  • Pexidartinib (JP/Asia)
    CSF-1/KIT/FLT3 inhibitor
    Tenosynovial giant cell tumor
  • Esaxerenone (JP)
    MR blocker
    Diabetic nephropathy
  • VN-0102/JVC-001 (JP)
    Measles mumps rubella
    combined vaccine
  • DS-5670 (JP)
    SARS-CoV-2 mRNA vaccine
    COVID-19 (booster vaccination)

Submitted

  • Valemetostat (DS-3201) (JP)
    EZH1/2 inhibitor
    ATL/L
  • VN-0107/MEDI3250 (JP)
    Live attenuated influenza vaccine nasal spray